



Review Article

RASAYANA THERAPY IN AYURVEDA: POTENTIAL ROLE IN CANCER PREVENTION AND SURVIVORSHIP

Manish Kumar Sharma^{1*}, Priyanka Sharma²

¹Ph.D Scholar, Department of Kriya Sharir, PGIA, DSRRAU, Jodhpur,

²Assistant Professor, Department of Panchakarma, Dr. Sarvesh Kumar Shukla Ayurvedic Medical College, Bahraich, Uttar Pradesh, India.

Article info

Article History:

Received: 11-08-2025

Accepted: 09-09-2025

Published: 30-09-2025

KEYWORDS:

Rasayana, Cancer Prevention, Cancer Survivorship, Integrative Oncology, Adaptogen, Immuno-modulation.

ABSTRACT

Rasayana therapy, a cornerstone of Ayurveda, the traditional Indian system of medicine, is a holistic regimen focused on rejuvenation, enhancing longevity, and improving overall health and resilience. **Objective:** This review aims to critically evaluate the scientific evidence supporting the potential of *Rasayana* therapy in the realms of cancer prevention and management of cancer survivorship issues, aligning its traditional principles with modern pharmacological and clinical findings. **Methods:** A narrative review of published literature was conducted using databases such as PubMed, Scopus, Google Scholar, and the AYUSH Research Portal. Search terms included "*Rasayana*," "Ayurveda cancer," "adaptogen," "immunomodulation," "antioxidant," "apoptosis," alongside specific herbs like *Ashwagandha*, *Curcuma longa*, *Tinospora cordifolia*, and *Emblica officinalis*. **Results:** Preclinical studies robustly demonstrate that key *Rasayana* herbs possess multifaceted anti-cancer properties, including potent antioxidant activity, induction of apoptosis, inhibition of angiogenesis and metastasis, modulation of detoxification enzymes, and enhancement of immune function. These effects are mediated through the regulation of key signalling pathways such as NF- κ B, STAT3, and PI3K/AKT. Clinically, *Rasayana* therapy shows promise in improving the quality of life (QoL), reducing cancer-related fatigue, mitigating chemotherapy-induced toxicities (myelosuppression, neuropathy), and potentially enhancing chemoradiotherapy efficacy through radioprotective and chemosensitizing effects. **Conclusion:** *Rasayana* therapy presents a compelling, multi-targeted adjunctive approach in oncology. Its principles of enhancing host defense (*Vyadhikshamatva*) align with goals of preventing carcinogenesis and supporting survivors. While the existing evidence is promising, further high-quality, rigorous clinical trials are essential to standardize formulations, establish safety profiles, and integrate these ancient wisdom-based interventions into modern evidence-based oncologic care.

INTRODUCTION

Cancer remains a leading cause of morbidity and mortality worldwide, with its incidence projected to rise significantly in the coming decades^[1]. While advancements in conventional therapies like surgery, chemotherapy, radiotherapy, and immunotherapy have improved survival rates, they are often associated

with severe side effects, diminished quality of life (QoL), and long-term sequelae for survivors^[2]. Furthermore, the primary prevention of cancer through modifiable lifestyle and dietary factors is a critical yet underutilized strategy. This landscape has fuelled interest in complementary and integrative medicine (CIM) approaches to support conventional care, mitigate adverse effects, and address the holistic well-being of patients^[3].

Ayurveda, a 5000-year-old holistic medical system originating in India, offers a unique perspective on health and disease, emphasizing balance (*Swasthya*) among an individual's body, mind, and spirit. Its approach to cancer, broadly described as *Arbuda* or

Access this article online

Quick Response Code



<https://doi.org/10.47070/ayushdhara.v12i4.2219>

Published by Mahadev Publications (Regd.)
publication licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0
International (CC BY-NC-SA 4.0)

Granthi (depending on the presentation), involves complex imbalances of the *Tridosha* (*Vata*, *Pitta*, *Kapha*), the formation of *Ama* (toxins), and diminished *Ojas* (vital essence and immunity) [4].

A pivotal branch of Ayurveda is *Rasayana* therapy. The term "*Rasayana*" translates to the pathway (*Ayana*) of essence (*Rasa*), pertaining to the nourishment of all bodily tissues. It encompasses a set of regimens including specific herbal formulations, diet (*Ahara*), lifestyle (*Vihara*), and conduct aimed at promoting longevity, enhancing mental clarity, preventing disease, and rejuvenating the entire system [5]. The core objective of *Rasayana* is to increase *Ojas* and *Bala* (strength), thereby boosting *Vyadhikshamatva* (resistance against disease), a concept that closely parallels modern immunology and the idea of enhancing host defense against pathologies like cancer [6].

This manuscript explores the scientific rationale and evidence supporting the potential role of *Rasayana* therapy in two key areas of oncology: (1) Cancer Prevention, by targeting fundamental processes like oxidative stress, inflammation, and mutagenesis; and (2) Cancer Survivorship, by managing treatment-related toxicities, improving QoL, and potentially reducing the risk of recurrence.

The Principles of *Rasayana* Therapy

Rasayana is not merely a set of herbal drugs; it is a comprehensive process. Classical texts like *Charaka Samhita* describe it as a means to achieve optimum health by:

1. Slowing the aging process (*Vayahsthapana*)
2. Enhancing memory and intellect (*Medha*)
3. Providing disease resistance (*Vyadhikshamatva*)
4. Promoting lustre and vitality (*Prabha*)
5. Nourishing all bodily tissues (*Dhatu*)

Rasayanas are classified based on their method of administration (e.g., *Kutipravesika* - intensive indoor regimen, *Vatatapika* - outdoor regimen), their primary action (e.g., *Kamya* for health promotion, *Naimittika* for disease-specific purposes), and their medicinal form [7]. In the context of modern pharmacology, many *Rasayana* plants are recognized as "adaptogens" substances that enhance the body's non-specific resistance to stress, normalize physiological functions, and have a protective effect against a wide variety of environmental challenges [8].

Mechanistic Basis for Anti-Cancer Effects of *Rasayana*

The anti-carcinogenic potential of *Rasayana* herbs is supported by their multi-targeted effects on various hallmarks of cancer.

- **Antioxidant and Anti-mutagenic Activity** Oxidative stress and DNA damage are fundamental initiators of carcinogenesis. Many *Rasayanas* are rich reservoirs of antioxidants like vitamins, flavonoids, tannins, and phenols. *Emblica officinalis* (*Amalaki*) exhibits significant free radical scavenging activity, protecting cellular macromolecules from oxidative damage and preventing mutagenesis [9]. *Asparagus racemosus* (*Shatavari*) and *Tinospora cordifolia* (*Guduchi*) have also demonstrated potent antigenotoxic effects in various models [10].
- **Immunomodulation** A robust immune system is critical for immune surveillance and the elimination of nascent tumour cells. *Rasayana* therapy is renowned for its immunostimulatory properties. *Tinospora cordifolia* and *Withania somnifera* (*Ashwagandha*) have been shown to enhance phagocytosis by macrophages, stimulate natural killer (NK) cell activity, and promote the proliferation of lymphocytes and the production of cytokines like IL-2 and IFN- γ , thereby bolstering both innate and adaptive immunity [11,12].
- **Apoptosis Induction and Inhibition of Proliferation** A key strategy in cancer control is the selective induction of apoptosis (programmed cell death) in malignant cells. Curcumin from *Curcuma longa* (turmeric) is a well-established pro-apoptotic agent, downregulating anti-apoptotic proteins (Bcl-2) and activating caspase cascades in numerous cancer cell lines [13]. Withaferin A, from *Withania somnifera*, induces apoptosis by generating reactive oxygen species (ROS) and inhibiting the PI3K/Akt pathway in breast and colon cancer cells [14].
- **Anti-angiogenesis and anti-metastasis** tumor growth and spread depend on angiogenesis (formation of new blood vessels) and metastasis. Curcumin and other *Rasayana* compounds inhibit key pro-angiogenic factors like VEGF (Vascular Endothelial Growth Factor) and MMPs (Matrix Metalloproteinases), thereby restricting tumor neovascularization and invasion [15].
- **Detoxification enzyme modulation** *Rasayanas* can modulate the activity of Phase I and Phase II xenobiotic-metabolizing enzymes. They may inhibit cytochrome P450 enzymes that activate procarcinogens while upregulating glutathione S-transferase (GST) and other conjugating enzymes that facilitate the excretion of toxins and potential carcinogens [16].
- **Adaptation to stress (adaptogenic effect)** The diagnosis and treatment of cancer are profound physical and psychological stressors. The adaptogenic properties of herbs like *Ashwagandha* help modulate the hypothalamic-pituitary-adrenal (HPA) axis, reduce cortisol levels, and improve

resilience, which can indirectly influence cancer progression and patient coping [17].

Role in Cancer Prevention

The mechanisms described above provide a strong scientific basis for the chemo preventive potential of *Rasayana* therapy. By combating oxidative stress, enhancing DNA repair mechanisms, boosting immune surveillance, and facilitating the detoxification of carcinogens, *Rasayana* regimens could potentially delay or prevent the initiation and promotion of cancer. Population studies suggest that dietary patterns rich in spices and herbs used in Ayurveda, such as turmeric, are associated with lower rates of certain cancers in India [18]. While large-scale human trials are needed, the cumulative evidence from pre-clinical studies supports the inclusion of *Rasayana* principles- a diet and lifestyle rich in antioxidants and immune-boosting agents- as a strategic component of public health cancer prevention initiatives.

Role in Cancer Survivorship and Supportive Care

This is perhaps the most immediate and evidence-supported application for *Rasayana* in oncology.

- **Ameliorating Chemo/Radiotherapy Toxicity:** Numerous studies show that *Rasayana* herbs can protect healthy tissues from the damaging effects of cancer treatment. *Tinospora cordifolia* has been shown in clinical studies to reduce the incidence and severity of chemotherapy-induced myelosuppression (neutropenia, thrombocytopenia), thereby reducing the need for dose reductions and growth factor support [19]. *Ashwagandha* has demonstrated efficacy in improving fatigue and QoL scores in breast cancer patients undergoing chemotherapy and reducing the symptoms of chemotherapy-induced neuropathy [20,21].
- **Radio-protective and Chemo-sensitizing Effects:** Some *Rasayanas* exhibit a fascinating "differential effect." They protect normal cells from radiation damage while sensitizing cancer cells to radiotherapy and chemotherapy. *Ocimum sanctum* (Holy Basil) and *Embllica officinalis* have demonstrated significant radioprotective effects in animal models, likely due to their free radical scavenging properties [22]. Curcumin, meanwhile, can sensitize tumor cells to chemoagents like 5-FU and oxaliplatin by suppressing pathways that confer drug resistance [23].
- **Improving Quality of Life (QoL) and Mental Health:** The adaptogenic and anxiolytic properties of *Rasayanas* like *Ashwagandha* are highly relevant for survivors dealing with anxiety, depression, and cancer-related fatigue (CRF). Clinical trials have reported significant improvements in stress scores,

sleep quality, and overall well-being with standardized extracts [17, 24].

Challenges and Future Directions

Despite the promising evidence, several challenges remain:

- **Standardization and Quality Control:** The efficacy of herbal preparations depends on the plant's genus, part used, season of harvest, geographical source, and extraction method. Standardized extracts with defined phytochemical markers are crucial for reproducible research and clinical application.
- **Herb-Drug Interactions (HDIs):** Potential interactions between *Rasayana* herbs and conventional cancer drugs are a major concern. For example, some herbs may inhibit or induce cytochrome P450 enzymes or P-glycoprotein, altering the pharmacokinetics of chemotherapeutic agents [25]. Rigorous pharmacovigilance studies are essential.
- **Evidence Gap:** While preclinical data is abundant, large-scale, randomized, placebo-controlled, double-blind clinical trials (RCTs) with robust endpoints are limited. Future research must focus on well-designed RCTs to generate Level I evidence.
- **Integration into Modern Oncology:** A collaborative model involving Ayurvedic physicians and oncologists is needed to develop safe, effective, and personalized integrative protocols.

CONCLUSION

Rasayana therapy, with its holistic foundation and multi-targeted pharmacologic actions, offers a valuable adjunct to modern oncology. Its potential spans from primary cancer prevention by strengthening the host's inherent defense mechanisms to providing critical support for survivors by alleviating treatment-related toxicities and enhancing overall quality of life. The scientific validation of its mechanisms- antioxidant, immunomodulatory, apoptogenic, and adaptogenic- provides a rational basis for its use. Moving forward, a concerted effort towards high-quality clinical research, standardization of products, and education of healthcare providers will be key to responsibly integrating this ancient wisdom into the future of comprehensive, patient-centered cancer care.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021; 71(3): 209-249.
2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin.* 2019; 69(5): 363-385.

3. Mao JJ, Pillai GG, Andrade CJ, et al. Integrative Oncology: Addressing the Global Challenges of Cancer Prevention and Treatment. *CA Cancer J Clin*. 2022; 72(2): 144-164.
4. Balachandran P, Govindarajan R. Cancer: an Ayurvedic perspective. *Pharmacol Res*. 2005; 51(1): 19-30.
5. Sharma PV. Charaka Samhita: Text with English Translation. Chaukhambha Orientalia; 1981.
6. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six Rasayana herbs used in Ayurvedic medicine. *Phytother Res*. 1999; 13(4): 275-291.
7. Singh RH. An introduction to the principles and practice of Rasayana therapy in Ayurveda. *Ayu*. 2011; 32(4): 446-451.
8. Panossian A, Wikman G. Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms Associated with Their Stress-Protective Activity. *Pharmaceuticals (Basel)*. 2010; 3(1): 188-224.
9. Bhattacharya A, Chatterjee A, Ghosal S, Bhattacharya SK. Antioxidant activity of active tannoid principles of *Emblica officinalis* (amla). *Indian J Exp Biol*. 1999; 37(7): 676-680.
10. Singh RP, Banerjee S, Kumar PV, Raveesha KA, Rao AR. *Tinospora cordifolia* induces enzymes of carcinogen/drug metabolism and antioxidant system, and inhibits lipid peroxidation in mice. *Phytomedicine*. 2006; 13(1-2): 74-84.
11. Mathew S, Kuttan G. Immunomodulatory and antitumour activities of *Tinospora cordifolia*. *Fitoterapia*. 1999; 70(1): 35-43.
12. Davis L, Kuttan G. Immunomodulatory activity of *Withania somnifera*. *J Ethnopharmacol*. 2000; 71(1-2): 193-200.
13. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. *Adv Exp Med Biol*. 2007; 595: 1-75.
14. Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. *AAPS J*. 2014; 16(1): 1-10.
15. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. *Clin Hemorheol Microcirc*. 2006; 34(1-2): 109-115.
16. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemical-induced genotoxicity in mice. *Mutat Res*. 2010; 700(1-2): 51-57.
17. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. *Indian J Psychol Med*. 2012; 34(3): 255-262.
18. Mohandas KM, Desai DC. Epidemiology of digestive tract cancers in India. V. Large and small bowel. *Indian J Gastroenterol*. 1999; 18(3): 118-121.
19. Mittal N, Shukla S, Rai G, et al. Efficacy of *Tinospora cordifolia* in myelosuppression during cancer chemotherapy. *J Clin Oncol*. 2006; 24(18_suppl): 18524.
20. Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of *Withania somnifera* (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. *Integr Cancer Ther*. 2013; 12(4): 312-322.
21. Kumar N, Kumar A, Sharma S, et al. Efficacy of Ashwagandha (*Withania somnifera* [L.] Dunal) in ameliorating chemotherapy-induced neuropathy in breast cancer patients: a double-blind, randomized, placebo-controlled trial. *Support Care Cancer*. 2023; 31(4): 221.
22. Devi PU, Ganasoundari A. Radioprotective effect of leaf extract of Indian medicinal plant *Ocimum sanctum*. *Indian J Exp Biol*. 1995; 33(3): 205-208.
23. Howells LM, Iwuji COO, Irving GRB, et al. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. *J Nutr*. 2019; 149(7): 1133-1139.
24. Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (*Withania somnifera*). *J Altern Complement Med*. 2014; 20(12): 901-908.
25. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. *J Clin Oncol*. 2004; 22(12): 2489-2503.

Cite this article as:

Manish Kumar Sharma, Priyanka Sharma. Rasayana Therapy in Ayurveda: Potential Role in Cancer Prevention and Survivorship. *AYUSHDHARA*, 2025;12(4):85-88.

<https://doi.org/10.47070/ayushdhara.v12i4.2219>

Source of support: Nil, Conflict of interest: None Declared

***Address for correspondence**

Dr. Manish Kumar Sharma

PhD Scholar,

Department of Kriya Sharir,

PGIA, DSRRAU Jodhpur, India.

Email: manish.star10@gmail.com

Disclaimer: AYUSHDHARA is solely owned by Mahadev Publications - A non-profit publications, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. AYUSHDHARA cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of AYUSHDHARA editor or editorial board members.